Programmable small molecules, precise transcriptional control

Platform

Our bifunctional editors can be built iteratively and rapidly using modular library synthesis

Each molecule is profiled transcriptome wide, surfacing on and off target biology

Data of unparalleled richness and relevance for rapid optimisation and early derisking

Targeted transcriptional editors are tools with extraordinary potential but massive delivery challenges

Lexicon is building a platform for transcriptional editing using small molecules that can go anywhere in the human body

Modular chemistry for rapid library synthesis

High throughput transcriptome-scale profiling

Unlock insight at scale for accelerated discovery and reduced risk

Lexicon’s discovery engine is built to turn high-throughput experiments into actionable decisions

Cloud native QC, analysis, scoring, and signature comparison, linked directly to chemical structure

Rapid library iteration is coupled to a massive and growing dataset of transcriptional data

Pipeline

We have already identified the first activators of a regenerative stem cell pathway, repressors of an undruggable transcription factor, and best-in-class molecules acting on a validated oncology pathway with an entirely novel mechanism.

Delivering transcriptional editing to areas of high unmet need:

  • Oncology

    • Metastatic castration resistant prostate cancer

  • Regenerative medicine

    • Heart failure with reduced ejection fraction

  • Immunology

    • Crohn’s disease and IBD

Team

Alfie Brennan

Founder

Prior to founding Lexicon Bio, Alfie was the cofounding CSO of Evariste, where he led the build out of the platform and the pipeline, including the discovery of PKMYT1 preclinical candidates. He has worked across multiple epigenetic targets and novel modalities, including degraders of BCL6, RIPK1, and MDM2.

Advisors

Lexicon is advised by industry leaders with decades of experience in bifunctional small molecules, epigenetic drug discovery, and clinical translation, including programs that have advanced into late-stage clinical development.